{"id":553659,"date":"2021-07-20T16:32:01","date_gmt":"2021-07-20T16:32:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=553659"},"modified":"2021-07-20T16:32:01","modified_gmt":"2021-07-20T16:32:01","slug":"short-bowel-syndrome-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/short-bowel-syndrome-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments_553659.html","title":{"rendered":"Short Bowel Syndrome Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1626783138.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Short Bowel Syndrome Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments\" src=\"https:\/\/www.abnewswire.com\/uploads\/1626783138.png\" alt=\"Short Bowel Syndrome Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s \u201cShort Bowel Syndrome Pipeline Insight\u201d report provides comprehensive insights about key companies and pipeline drugs in the Short Bowel Syndrome pipeline landscapes. It comprises Short Bowel Syndrome pipeline drug profiles, including clinical and non-clinical stage products. <\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight&rsquo;s <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/short-bowel-syndrome-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">&ldquo;<strong>Short Bowel Syndrome Pipeline Insight<\/strong>&rdquo;<\/a> report provides comprehensive insights about key companies&nbsp;and pipeline drugs in the Short Bowel Syndrome pipeline landscapes. It comprises Short Bowel Syndrome pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Short Bowel Syndrome therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Short Bowel Syndrome pipeline products.&nbsp; &nbsp; &nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/974a4fc666bafd63d6a87bc6a1203bdc.jpg\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Some of the key takeaways of the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/short-bowel-syndrome-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Short Bowel Syndrome Pipeline Report<\/a><\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as<\/span><span data-mce-mark=\"1\"> Zealand Pharma, VectivBio\/The rachon AG, <\/span><span data-mce-mark=\"1\">etc., are developing therapies for the treatment of Short Bowel Syndrome.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Emerging therapies such as <\/span><span data-mce-mark=\"1\">&nbsp;Glepaglutide, Apraglutide, <\/span><span data-mce-mark=\"1\">are expected to have a significant impact on the <\/span><span data-mce-mark=\"1\">&nbsp;Short Bowel Syndrome <\/span><span data-mce-mark=\"1\">market in the coming years.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">The growing prevalence of short bowel syndrome is expected to drive the growth of the SBS market.&nbsp;<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Get an overview of pipeline landscape @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/short-bowel-syndrome-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Short Bowel Syndrome Clinical Trials Analysis <\/a>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">Short bowel syndrome is a condition in which the body is not able to absorb enough of the food-to-eat food, because you have enough of the small intestine. The small intestine is the site where most of the food is absorbed into your body during the digestion of food.&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Short Bowel Syndrome Emerging Drugs<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Glepaglutide by Zealand Pharma<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Apraglutide by VectivBio\/The rachon AG<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">And others.<\/span><\/p>\n<\/li>\n<\/ol>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\"><strong>Scope of Short Bowel Syndrome Pipeline Drug Insight&nbsp;<\/strong>&nbsp;&nbsp;&nbsp;<\/span><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Coverage: <\/span><span data-mce-mark=\"1\">Global&nbsp;<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Major Players:<\/span><span data-mce-mark=\"1\"> Zealand Pharma, VectivBio\/The rachon AG, and others.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Pipeline Therapies:<\/span><span data-mce-mark=\"1\"> Glepaglutide, Apraglutide, and others.<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Contents<\/strong><\/p>\n<div style=\"text-align: justify;\" dir=\"ltr\" align=\"left\">\n<table>\n<colgroup>\n<col width=\"22\" \/>\n<col width=\"386\" \/><\/colgroup>\n<tbody>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">1<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Short Bowel Syndrome Report Introduction<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">2<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Short Bowel Syndrome Executive Summary<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">3<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Short Bowel Syndrome Overview<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">4<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Short Bowel Syndrome- Analytical Perspective In-depth Commercial Assessment<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">5<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Short Bowel Syndrome Pipeline Therapeutics<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">6<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Short Bowel Syndrome Late Stage Products (Phase II\/III)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">7<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Short Bowel Syndrome Mid Stage Products (Phase II)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">8<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Short Bowel Syndrome Early Stage Products (Phase I)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">9<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Short Bowel Syndrome Preclinical Stage Products<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">10<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Short Bowel Syndrome Therapeutics Assessment<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">11<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Short Bowel Syndrome Inactive Products<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">12<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Company-University Collaborations (Licensing\/Partnering) Analysis<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">13<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Short Bowel Syndrome Key Companies<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">14<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Short Bowel Syndrome Key Products<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">15<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Short Bowel Syndrome Unmet Needs<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">16&nbsp;<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Short Bowel Syndrome Market Drivers and Barriers<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">17<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Short Bowel Syndrome Future Perspectives and Conclusion<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">18<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Short Bowel Syndrome Analyst Views<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">19<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Appendix<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">20<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">About DelveInsight<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Get a customized pipeline report @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/short-bowel-syndrome-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Short Bowel Syndrome Drugs Pipeline Report<\/a>&nbsp;&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Related Reports:<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Short Bowel Syndrome Market&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">DelveInsight&#8217;s Short Bowel Syndrome &#8211; Market Insights, Epidemiology, and Market Forecast-2030 report deliver an in-depth understanding of the Short Bowel Syndrome, historical and forecasted epidemiology as well as the Short Bowel Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\"><strong>Short Bowel Syndrome Epidemiology<\/strong><\/span><\/p>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s &#8216; Short Bowel Syndrome- Epidemiology Forecast to 2030&#8217; report delivers an in-depth understanding of the disease, historical and forecasted&nbsp; Short Bowel Syndrome epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=short-bowel-syndrome-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=short-bowel-syndrome-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight\u2019s \u201cShort Bowel Syndrome Pipeline Insight\u201d report provides comprehensive insights about key companies and pipeline drugs in the Short Bowel Syndrome pipeline landscapes. It comprises Short Bowel Syndrome pipeline drug profiles, including clinical and non-clinical stage &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/short-bowel-syndrome-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments_553659.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-553659","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/553659","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=553659"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/553659\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=553659"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=553659"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=553659"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}